NCT07335757

Brief Summary

Acute pancreatitis (AP), defined as acute inflammation of the pancreas, it's one of the most common diseases of the gastrointestinal tract leading to hospital admission.(1) The global incidence of AP is reported between 20 and 40 cases per 100,000 individuals, with an increasing trend over recent decades. (2) Its severity ranges from mild self-limited disease to severe acute necrotizing pancreatitis characterized by systemic complications and multi-organ failure. AKI is a frequent complication of severe acute pancreatitis, usually after the failure of other organs. (3) The aetiology of AP can be readily established in most patients. The most common causes include gallstones (40%-70%) and alcohol (25%-35%), medications as 6-mercaptopurine and azathioprine clearly can cause AP, infectious agents, and metabolic causes such as hypercalcemia and hypertriglyceridemia are rare causes (4) Acute kidney injury (AKI), affects approximately 15% of AP patients increasing to 69% in severe AP cases. AKI not only worsens the clinical status of AP patients but also significantly increases mortality risk and the likelihood of progressing to chronic kidney disease (CKD. Therefore, the challenge of early AKI identification and timely therapeutic intervention in AP patients remains critical. (2) Albumin (ALB), a negative acute-phase reactant synthesized by the liver, constitutes 40% to 60% of total plasma protein and decreases during inflammation. (5) Serum CRP refers to a positive acute phase reactant synthesized by the liver and its level in the blood elevates within hours as a response to inflammation and infection and it can be applied in follow-up owing to the short half-life, easy measurement, as well as the close association with prognosis of the disease. (6) We aimed to assess the Correlation between C-Reactive Protein to Albumin Ratio (CAR) and Acute Kidney Injury (AKI) in Patients with Acute Pancreatitis (AP) as a cost-effective, easily accessible, and reproducible prognostic biomarkers for inflammation obtained from standard blood tests.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
34mo left

Started Jan 2026

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress9%
Jan 2026Jan 2029

First Submitted

Initial submission to the registry

January 2, 2026

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 13, 2026

Completed
17 days until next milestone

Study Start

First participant enrolled

January 30, 2026

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2029

Last Updated

January 13, 2026

Status Verified

January 1, 2026

Enrollment Period

3 years

First QC Date

January 2, 2026

Last Update Submit

January 2, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • assessment of correlation between CRP/Alb ratio (CAR) and AKI in patients with acute pancreatitis (AP).

    10 days

Interventions

Correlation between C-Reactive Protein to Albumin Ratio (CAR) and Acute Kidney Injury in Patients with Acute Pancreatitis

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

patients with acute pancreatitis

You may qualify if:

  • )patients who were diagnosed with Acute Pancreatitis by the following criteria: (i) abdominal pain mostly referred to the back, (ii) serum amylase and/or lipase greater than 3 times the upper limit of normal, and/or (iii) diagnostic findings from imaging (CT abdomen). 2)patients over 18 years old.

You may not qualify if:

  • \) Pregnant or breastfeeding women 2)Length of hospital stay ≤ 24 h 3) Patients with CKD or end-stage renal disease. 4)patients with active malignancy. 5)patients with liver cirrhosis. 6)patients with active infections or surgeries

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Wu W, Zhang YP, Pan YM, He ZJ, Tan YP, Wang DD, Qu XG, Zhang ZH. Predictive Value of C-Reactive Protein/Albumin Ratio for Acute Kidney Injury in Patients with Acute Pancreatitis. J Inflamm Res. 2024 Aug 16;17:5495-5507. doi: 10.2147/JIR.S473466. eCollection 2024.

  • Tenner S, Vege SS, Sheth SG, Sauer B, Yang A, Conwell DL, Yadlapati RH, Gardner TB. American College of Gastroenterology Guidelines: Management of Acute Pancreatitis. Am J Gastroenterol. 2024 Mar 1;119(3):419-437. doi: 10.14309/ajg.0000000000002645. Epub 2023 Nov 7.

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Central Study Contacts

Noha Fathy Radwan, Msc

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
dr

Study Record Dates

First Submitted

January 2, 2026

First Posted

January 13, 2026

Study Start

January 30, 2026

Primary Completion (Estimated)

January 30, 2029

Study Completion (Estimated)

January 30, 2029

Last Updated

January 13, 2026

Record last verified: 2026-01